History    2000-

Aiming to be a World-class Pharmaceutical Company with Japanese Origin

2000

The right to access and utilize the databases of Celera Genomics obtained

Utilizing Celera's genomic information, Takeda has been facilitating our discovery research on orphan receptors and ligands and to discover unknown enzyme genes and disease-related genes.

Restructuring non-pharmaceutical businesses began

In order to concentrate management resources into pharmaceutical businesses, Takeda has been restructuring animal health business, bulk vitamin business, urethane chemicals business, food business, agro business and life-environment business our non-pharmaceutical businesses as originally planned in the 2001-2005 Medium-Term Management Plan.

2001

, investment company,established in the U.S.

2002

All the Shares of Takeda Pharma GmbH aquired, a pharmaceutical marketing company in Germany

and its 100% owned subsidiaries (one in Austria "" and the other in Switzerland "") became a 100% subsidiary of Takeda Europe Holdings Ltd.

a pharmaceutical bulk plant, established

It is our first bulk pharmaceutical manufacturing site outside Japan. Takeda aims to minimize costs by establishing manufacturing operations in convenient locations worldwide.

2003

, established in the U.S.

Takeda has integrated the development function in the U.S., Europe and Japan. By reinforcing the development system and its function at a global level, Takeda aims to accelerate the progress of development stages of our products and to achieve its early launch onto the market in the tri-polar markets.

2005

Merge Syrrx, Inc. into the Takeda Group as the research base in the U.S.

The company changed its name to

Insomnia treatment Rozerem™ launched in the U.S.

2006

Takeda Pharmaceuticals Europe Limited established in U.K.

Takeda Pharmaceuticals Europe Limited leads operations in Europe and accelerates pan-European strategies for the medium to long term.

New U.S. home office established

The opening of the new home offices in the United States is one of the greatest achievements for establishing and enhancing Takeda's U.S. business.

2007

Merge Paradigm Therapeutics Limited as the new research base

Takeda now has research functions in Japan, the U.S., Europe, and in Singapore. This acquisition surely represents our initiatives for establishing global research infrastructures and for pursuing the world's highest standard of productivity.
The company and its subsidiary renamed and Takeda Singapore Pte Limited.